Emergent BioSolutions wins USD 52.7 million US government contract modification for ACAM2000 vaccine supply

Emergent BioSolutions Inc.

Emergent BioSolutions Inc.

EBS

0.00
  • Emergent BioSolutions received a contract modification worth USD 52.7 million from HHS’s ASPR for ACAM2000 smallpox and mpox vaccine supply.
  • Work covers vaccine doses, related ancillaries, and diluent replacement lots for US smallpox preparedness and response.
  • Deliveries are expected to start this month under an existing 10-year ASPR contract.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Emergent BioSolutions Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606290913PRIMZONEFULLFEED9754027) on June 29, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.